title: European consensus table on the use of botulinum toxin type A in adult spasticity.
abstract: A group of clinicians from across Europe experienced in the use of botulinum toxin type A for the treatment of spasticity following acquired brain injury gathered to develop a consensus statement on best practice in managing adults with spasticity. This consensus table summarizes the current published data, which was collated following extensive literature searches, their assessment for level of evidence and discussion among the whole group. Published information is supplemented by expert opinion based on clinical experience from 16 European countries, involving 28 clinicians, who treat an average of approximately 200 patients annually, representing many thousand spasticity treatments with botulinum toxin per year.
authors.affiliation: Kliniken Beelitz GmbH, Clinical Department of Neurological Rehabilitation, Beelitz-Heilstaetten, Germany. wissel@rehaklinik-beelitz.de
authors.forename: Jörg
authors.initials: J
authors.lastname: Wissel
authors.forename: Anthony B
authors.initials: AB
authors.lastname: Ward
authors.forename: Per
authors.initials: P
authors.lastname: Erztgaard
authors.forename: Djamel
authors.initials: D
authors.lastname: Bensmail
authors.forename: Martin J
authors.initials: MJ
authors.lastname: Hecht
authors.forename: Thierry M
authors.initials: TM
authors.lastname: Lejeune
authors.forename: Peter
authors.initials: P
authors.lastname: Schnider
authors.forename: Maria C
authors.initials: MC
authors.lastname: Altavista
authors.forename: Stefano
authors.initials: S
authors.lastname: Cavazza
authors.forename: Thierry
authors.initials: T
authors.lastname: Deltombe
authors.forename: Esther
authors.initials: E
authors.lastname: Duarte
authors.forename: Alexander C H
authors.initials: AC
authors.lastname: Geurts
authors.forename: Jean-Michel
authors.initials: JM
authors.lastname: Gracies
authors.forename: Naseer H J
authors.initials: NH
authors.lastname: Haboubi
authors.forename: Francisco J
authors.initials: FJ
authors.lastname: Juan
authors.forename: Helge
authors.initials: H
authors.lastname: Kasch
authors.forename: Christian
authors.initials: C
authors.lastname: Kätterer
authors.forename: Yeşim
authors.initials: Y
authors.lastname: Kirazli
authors.forename: Paolo
authors.initials: P
authors.lastname: Manganotti
authors.forename: Yeşim
authors.initials: Y
authors.lastname: Parman
authors.forename: Tatjana
authors.initials: T
authors.lastname: Paternostro-Sluga
authors.forename: Konstantina
authors.initials: K
authors.lastname: Petropoulou
authors.forename: Robert
authors.initials: R
authors.lastname: Prempeh
authors.forename: Marc
authors.initials: M
authors.lastname: Rousseaux
authors.forename: Jaroslaw
authors.initials: J
authors.lastname: Slawek
authors.forename: Niko
authors.initials: N
authors.lastname: Tieranta
mesh_terms: D000328:Adult; D019274:Botulinum Toxins, Type A / Q000008:administration & dosage*; D020208:Brain Injury, Chronic / Q000150:complications; D032921:Consensus; D019317:Evidence-Based Medicine; D005500:Follow-Up Studies; D006801:Humans; D002534:Hypoxia, Brain / Q000150:complications; D007273:Injections, Intramuscular; D009043:Motor Activity / Q000187:drug effects; D016472:Motor Neuron Disease / Q000188:drug therapy* / Q000209:etiology; D009128:Muscle Spasticity / Q000188:drug therapy* / Q000209:etiology; D009465:Neuromuscular Agents / Q000008:administration & dosage*; D020521:Stroke / Q000150:complications
chemical_list: D009465:Neuromuscular Agents; D019274:Botulinum Toxins, Type A